[1] Siegel
RL, Miller KD, Jemal A.Cancer statistics, 2017[J].CA Cancer J Clin,
2017,67(1):7-30. DOI:10.3322/caac.20073.
[2] 张胜捷,姜伟,袁逸民,等. 改良Gleason评分系统在前列腺癌术后患者预后评估中的意义[J]. 中华泌尿外科杂志,2016,37(5):344-348. DOI:10.3760/cma.j.issn.1000-6702.2016. 05.007.
[3] 周祥福.2018版欧洲泌尿外科前列腺癌指南要点解读[J/CD].中华腔镜泌尿外科杂志(电子版),2018,12(5):289-294. DOI:10.3877/cma.j.issn.1674-3253.2018. 05.001.
[4] 顾成元,秦晓健,黄永墙,等. 我国部分省市前列腺癌精准筛查初步结果分析[J]. 中华医学杂志,2019,99(42):3292-3297.
DOI:10.3760/cma.j.issn.0376-2491.2019. 42.004.
[5] 宋震宇,胡华,刘勇,等. 前列腺癌ADC值与Gleason评分及Ki-67、P53蛋白表达的相关性[J]. 中国医学影像技术,2019,35(2):236-239. DOI:10.13929/j.1003- 3289.201806056.
[6] Wu X, Reinikainen P, Vanhanen A, et al.
Correlation between apparent diffusion coefficient value on diffusion-weighted
MR imaging and Gleason score in prostate cancer[J].Diagn Interv
Imaging,2017,98(1):63-71. DOI:10.1016/j.diii.2016.08.009.
[7] Sokmen BK, Sokmen D, Ucar N, et al. The
correlation between biological activity and diffusion-weighted MR imaging and
ADC value in cases with prostate cancer[J].Arch Ital Urol
Androl,2017,89(4):277-281. DOI:10.4081/aiua.2017.4.277. PMID: 29473377.
[8] 赵素红,郭卫华,陈佩佩,等. DWI最小表观扩散系数诊断乳腺导管内癌和浸润性癌的价值[J]. 实用放射学杂志,2018,34(5):686-689. DOI:10.3969/j.issn.1002-1671.2018.
05.010.
[9] 王亚婷,陈伟,张晰,等. 表观扩散系数最小值和平均值与肾透明细胞癌病理分级的相关性研究[J]. 实用放射学杂志,2019,35(12):1974-1977.
DOI:10.3969/j.issn.1002- 1671. 2019.12.021.
[10] 漆万银,程勇,杨述根. 扩散加权成像评估子宫内膜癌淋巴血管间隙侵犯的价值[J]. 放射学实践,2021,36(2):222-226. DOI:10.13609/j.cnki.1000-0313.2021.02.014.
[11] 陈伟,王亚婷,周海飞,等. ADC平均值及最小值与食管癌病理特点的相关性分析[J]. 放射学实践,2019,34(9):1002-1006.
DOI:10.13609/j.cnki.1000-0313.2019.09.014.
[12] Aslan K, Gunbey HP, Tomak L, et al. The
diagnostic value of using combined MR diffusion tensor imaging parameters to
differentiate between low- and high-grade meningioma[J].Br J
Radiol,2018,91(1088):20180088. DOI:10.1259/bjr.20180088.
[13] Tamada T, Prabhu V, Li J, et al.
Assessment of prostate cancer aggressiveness using apparent diffusion
coefficient values: impact of patient race and age[J].Abdom Radiol
(NY),2017,42(6):1744-1751. DOI:10.1007/s00261-017-1058-y.
[14] Alessandrino F, Taghipour M, Hassanzadeh
E, et al. Predictive role of PI-RADSv2 and ADC parameters in differentiating
Gleason pattern 3 + 4 and 4 + 3 prostate cancer[J].Abdom Radiol
(NY),2019,44(1):279-285. DOI:10.1007/s00261-018-1718-6.
[15] 赵醒艳. ADC值和标化ADC值对前列腺癌患者盆腔转移性淋巴结的诊断价值[J]. 临床放射学杂志,2019,38(1):122-125. DOI:10.13437/j.cnki.jcr.2019.01.028.
[16] Barrett T, Priest AN, Lawrence EM, et
al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as
a method for quantifying DWI of the prostate[J].AJR Am J
Roentgenol,2015,205(6):W585-W593. DOI:10.2214/AJR.15.14338.
[17] De Cobelli F, Ravelli S, Esposito A, et
al. Apparent diffusion coefficient value and ratio as noninvasive potential
biomarkers to predict prostate cancer grading: comparison with prostate biopsy
and radical prostatectomy specimen[J].AJR Am J Roentgenol,2015,204(3):550-557.
DOI:10.2214/AJR.14.13146.
[18] Boesen L, Chabanova E, Løgager V, et al.
Apparent diffusion coefficient ratio correlates significantly with prostate
cancer gleason score at final pathology[J].J Magn Reson
Imaging,2015,42(2):446-453. DOI:10.1002/jmri.24801.
[19] Lee SY, Jee WH, Yoo IR, et al.
Comparison of 3T diffusion-weighted MRI and 18F-FDG PET/CT in musculoskeletal
tumours: quantitative analysis of apparent diffusion coefficients and
standardized uptake values[J].Br J Radiol,2019,92(1102):20181051.
DOI:10.1259/bjr.20181051.
[20] Shen Y, Lv F, Xiao Z, et al. Utility of
the relative apparent diffusion coefficient for preoperative assessment of low
risk endometrial carcinoma[J].Clin Imaging,2019,56:28-32.
DOI:10.1016/j.clinimag.2019.03.001.
[21] Jyoti R, Jain TP, Haxhimolla H, et al.
Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate
cancer Gleason score[J].Eur J Radiol Open,2018,5:58-63.
DOI:10.1016/j.ejro.2018.03.002.
|